Physiologically based pharmacokinetic modelling of oxycodone drug–drug interactions
- 10 January 2020
- journal article
- research article
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 41 (1-2) , 72-88
Abstract
Oxycodone is an opioid analgesic with several pharmacologically active metabolites and relatively narrow therapeutic index. Cytochrome P450 (CYP) 3A4 and CYP2D6 play major roles in the metabolism of oxycodone and its metabolites. Thus, inhibition and induction of these enzymes may result in substantial changes in the exposure of both oxycodone and its metabolites. In this study, a physiologically based pharmacokinetic (PBPK) model was built using GastroPlus™ software for oxycodone, two primary metabolites (noroxycodone, oxymorphone) and one secondary metabolite (noroxymorphone). The model was built based on literature and in house in vitro and in silico data. The model was refined and verified against literature clinical data after oxycodone administration in the absence of drug–drug interactions (DDI). The model was further challenged with simulations of oxycodone DDI with CYP3A4 inhibitors ketoconazole and itraconazole, CYP3A4 inducer rifampicin and CYP2D6 inhibitor quinidine. The magnitude of DDI (AUC ratio) was predicted within 1.5‐fold error for oxycodone, within 1.8‐fold and 1.3–4.5‐fold error for the primary metabolites noroxycodone and oxymorphone, respectively, and within 1.4–4.5‐fold error for the secondary metabolite noroxymorphone, when compared to the mean observed AUC ratios. This work demonstrated the capability of PBPK model to simulate DDI of the administered compounds and the formed metabolites of both DDI victim and perpetrator. However, the predictions for the formed metabolites tend to be associated with higher uncertainty than the predictions for the administered compound. The oxycodone model provides a tool for forecasting oxycodone DDI with other CYP3A4 and CYP2D6 DDI perpetrators that may be co‐administered with oxycodone.Keywords
This publication has 62 references indexed in Scilit:
- Inhibition of Cytochrome P450 3A by Clarithromycin Uniformly Affects the Pharmacokinetics and Pharmacodynamics of Oxycodone in Young and Elderly VolunteersJournal of Clinical Psychopharmacology, 2011
- Elimination of Intravenous Oxycodone in the ElderlyDrugs & Aging, 2011
- The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitorsJournal of Enzyme Inhibition and Medicinal Chemistry, 2010
- Grapefruit Juice Enhances the Exposure to Oral OxycodoneBasic & Clinical Pharmacology & Toxicology, 2010
- Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 aloneBritish Journal of Clinical Pharmacology, 2010
- Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safetyBritish Journal of Pharmacology, 2010
- The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodoneBritish Journal of Pharmacology, 2010
- Contribution of Itraconazole Metabolites to Inhibition of CYP3A4 In VivoClinical Pharmacology & Therapeutics, 2007
- The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantationJournal of Clinical Anesthesia, 1996
- Liposolubility and Protein Binding of Oxycodonein VitroBasic & Clinical Pharmacology & Toxicology, 1994